Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-25Clinical Trial Update: Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy [Phase 3]
Phase 3 trial assessing olanzapine to prevent vomiting in children and adolescents undergoing highly emetogenic chemotherapy; study not yet …
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV [Phase 3]
A Phase 3 clinical trial evaluating olanzapine in combination with a 5-HT3 receptor antagonist, with or without dexamethasone, to prevent ch…
-
FDA approval · 2025-05-29FDA Approved: FOCINVEZ — Supplemental Application (Steriscience Specialties Private Limited)
FDA approved a supplemental application for FOCINVEZ (fosaprepitant dimeglumine) from Steriscience Specialties Private Limited.
-
FDA approval · 2025-05-23FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Palonosetron hydrochloride submitted by Mylan Institutional LLC. This action updates the pro…
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: This Study Will Investigate the Effectiveness of Peppermint Oil Inhalation in Reducing the Intensity and Frequency of Acute Nausea and Vomiting Among Cancer Patients Undergoing Chemotherapy. Chemotherapy-induced Nausea and Vomiting (CINV) Are Among the Most Distressing Side Effects Experienced by pa [NA]
A clinical trial protocol to evaluate whether inhaled peppermint oil reduces the intensity and frequency of chemotherapy-induced nausea and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV) [Phase 2]
Phase 2 clinical trial evaluating aromatherapy for relief of chemotherapy-induced nausea and vomiting has completed and results have been po…
-
FDA approval · 2025-04-16FDA Approved: POSFREA — Supplemental Application (Avyxa Pharma, LLC)
The FDA approved a supplemental application for POSFREA (palonosetron) from Avyxa Pharma, LLC. The approval updates the product labeling to …
-
CLINICAL_TRIALS trial_result · 2025-04-13Clinical Trial Update: A Randomized Controlled Trial to Evaluate the Efficacy of Acupuncture Versus Aromatherapy as Treatments to Lessen Nausea, Vomiting and Anxiety Associated With Adriamycin and Cytoxan [NA]
A randomized controlled trial comparing acupuncture to aromatherapy evaluated their ability to lessen chemotherapy-induced nausea, vomiting,…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer [Phase 3]
Phase 3 trial evaluating the efficacy and safety of dronabinol for chemotherapy-induced and tumor-related symptoms in patients with advanced…
-
FDA approval · 2025-04-08FDA Approved: FOSAPREPITANT — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for fosaprepitant submitted by Mylan Institutional LLC, resulting in an updated approval of the …
-
FDA approval · 2025-03-25FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for palonosetron hydrochloride (generic) submitted by Eugia US LLC under ANDA204702, adding to t…
-
FDA approval · 2025-03-24FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for granisetron hydrochloride submitted by Eugia US LLC.
-
FDA approval · 2025-03-24FDA Approved: PALONOSETRON HYDROCHLORIDE — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for palonosetron hydrochloride submitted by Sagent Pharmaceuticals to support an approved indication…
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting [Phase 2]
A Phase 2 trial comparing a buccal film formulation of palonosetron to IV palonosetron for moderately emetogenic chemotherapy-induced nausea…
-
FDA approval · 2025-03-17FDA Approved: GRANISOL — Original Application (Intra-Sana Laboratories)
FDA approved GRANISOL (granisetron hydrochloride) through an original ANDA submission by Intra-Sana Laboratories, authorizing the generic pr…
-
CLINICAL_TRIALS research · 2025-03-11Clinical Trial Update: Predict CHimio-or Radiation-induced NAusea and Vomiting in Children/adolescents Treated for Cancer
A pediatric cancer trial update describes a study to predict chemotherapy- or radiation-induced nausea and vomiting in children, with recrui…
-
CLINICAL_TRIALS research · 2025-02-27Clinical Trial Update: Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy [Phase 3]
This Phase 3 trial compares olanzapine to placebo for preventing chemotherapy-induced nausea and vomiting in patients receiving moderately e…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: The Effect of Mandala on Nausea, Vomiting, Pain and Anxiety in Chemotherapy Patients [NA]
A completed clinical trial evaluating Mandala for nausea, vomiting, pain, and anxiety in patients undergoing chemotherapy.
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: The Effect of Mandala Technique on Acute Nausea-vomiting and Comfort Level in Cancer Patients [NA]
A completed clinical trial evaluating the Mandala Technique for reducing acute nausea and vomiting and improving comfort in cancer patients …
-
FDA approval · 2024-10-25FDA Approved: FOSAPREPITANT — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for fosaprepitant filed by BluePoint Laboratories.
-
FDA approval · 2024-10-18FDA Approved: FOSAPREPITANT — Supplemental Application (BE Pharmaceuticals Inc.)
FDA approved a supplemental application for fosaprepitant submitted by BE Pharmaceuticals Inc., resulting in an updated label under the ANDA…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: Anti-emetic Prophylaxis With or Without Dexamethasone [Phase 3]
A Phase 3 trial evaluating anti-emetic prophylaxis with or without dexamethasone in chemotherapy-induced nausea and vomiting has completed. …
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting [Phase 2]
The document describes a Phase 2 clinical trial evaluating the efficacy and safety of HSK21542 Injection for chemotherapy-induced nausea and…
-
FDA approval · 2024-09-16FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
The FDA approved a supplemental application for SANCUSO (granisetron) submitted by Cumberland Pharmaceuticals Inc.
-
FDA approval · 2024-09-16FDA Approved: FOSAPREPITANT — Supplemental Application (Avenacy, LLC)
FDA approved a supplemental application for Fosaprepitant (fosaprepitant dimeglumine) from Avenacy, LLC.